Significant Ownership of Stonepine Capital Management, LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Stonepine Capital Management, LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Jon M. Plexico - Managing Member
- Manager location
- Bend, OR
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Stonepine Capital Management, LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Stonepine Capital Management, LLC
Significant Ownership of Stonepine Capital Management, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | Ordinary Shares | 11% | $47,201,973 | +$3,465,711 | 3,271,100 | +7.9% | Stonepine Capital Management, LLC | 29 Jan 2026 |
| CRIS | CURIS INC | Common Stock | 9.9% | $4,468,851 | 4,025,992 | Stonepine Capital Management, LLC | 17 Mar 2026 | ||
| INAB | IN8BIO, Inc. | Common Stock | 9.9% | $1,975,660 | 1,007,990 | Stonepine Capital Management, LLC | 19 Dec 2025 | ||
| AYTU | AYTU BIOPHARMA, INC | Common Stock | 9.9% | $1,975,217 | 906,063 | Stonepine Capital Management, LLC | 30 Jun 2025 | ||
| SINT | SINTX Technologies, Inc. | Common Stock | 9.9% | $1,474,629 | 619,592 | Stonepine Capital Management, LLC | 02 Jun 2026 | ||
| CNSP | CNS Pharmaceuticals, Inc. | Common Stock | 9.9% | $402,671 | +$279,627 | 159,790 | +227% | Stonepine Capital Management, LLC | 31 Mar 2026 |
| AZTR | Azitra, Inc. | Common Stock | 9.9% | $244,207 | 1,744,339 | Stonepine Capital Management, LLC | 16 Jun 2026 | ||
| CLRB | Cellectar Biosciences, Inc. | Common Stock | 9.9% | 863,277 | Stonepine Capital Management, LLC | 04 May 2026 | |||
| Eloxx Pharmaceuticals, Inc. | Common Stock | 9.9% | 403,228 | Stonepine Capital Management, LLC | 09 Jun 2026 | ||||
| OPTN | OptiNose, Inc. | Common Stock | 7.8% | $7,176,688 | +$1,819,909 | 788,647 | +34% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| TELA | TELA Bio, Inc. | Common Stock | 6% | $2,211,913 | 2,353,099 | Stonepine Capital Management, LLC | 31 Dec 2024 | ||
| KTTA | Pasithea Therapeutics Corp. | Common Stock | 5.8% | $1,366,785 | 1,952,550 | Stonepine Capital Management, LLC | 17 Jun 2026 | ||
| CALC | CalciMedica, Inc. | Common Stock | 4.6% | $949,295 | -$170,674 | 628,672 | -15% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| VSTM | Verastem, Inc. | Common Stock | 4.3% | $23,576,383 | -$1,441,948 | 2,670,032 | -5.8% | Stonepine Capital Management, LLC | 30 Sep 2025 |
| APRE | Aprea Therapeutics, Inc. | Common Stock | 4.3% | $418,978 | -$82,213 | 239,416 | -16% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| INO | Inovio Pharmaceuticals, Inc. | Common Stock | 3.8% | $2,683,444 | -$900,721 | 1,434,997 | -25% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| TENX | Tenax Therapeutics, Inc. | Common Stock | 3.7% | $14,588,992 | 975,200 | Stonepine Capital Management, LLC | 31 Mar 2026 | ||
| SRZN | Surrozen, Inc./DE | Common Stock | 3.6% | $6,531,368 | -$3,973,019 | 316,289 | -38% | Stonepine Capital Management, LLC | 31 Dec 2025 |
| KZR | Kezar Life Sciences, Inc. | Common Stock | 2.1% | $968,310 | -$1,370,578 | 156,179 | -59% | Stonepine Capital Management, LLC | 31 Dec 2025 |
| EDSA | Edesa Biotech, Inc. | Common Stock | 0.3% | $177,000 | -$3,914,951 | 30,000 | -96% | Stonepine Capital Management, LLC | 31 Mar 2026 |
Schedules 13D/G Reported by Stonepine Capital Management, LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.